These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37080423)

  • 1. Historical Advances in Structural and Molecular Biology and How They Impacted Vaccine Development.
    Koff WC; Rappuoli R; Plotkin SA
    J Mol Biol; 2023 Jul; 435(13):168113. PubMed ID: 37080423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccinology: past achievements, present roadblocks and future promises.
    André FE
    Vaccine; 2003 Jan; 21(7-8):593-5. PubMed ID: 12531323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for viral diseases with dermatologic manifestations.
    Brentjens MH; Yeung-Yue KA; Lee PC; Tyring SK
    Dermatol Clin; 2003 Apr; 21(2):349-69. PubMed ID: 12757257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines in dermatological diseases.
    Magel GD; Mendoza N; Digiorgio CM; Haitz KA; Lapolla WJ; Tyring SK
    G Ital Dermatol Venereol; 2011 Jun; 146(3):225-33. PubMed ID: 21566552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in vaccine development for infectious diseases-a Keystone Symposia report.
    Cable J; Graham BS; Koup RA; Seder RA; Karikó K; Pardi N; Barouch DH; Sharma B; Rauch S; Nachbagauer R; Forsell MNE; Schotsaert M; Ellebedy AH; Loré K; Irvine DJ; Pilkington E; Tahtinen S; Thompson EA; Feraoun Y; King NP; Saunders K; Alter G; Moin SM; Sliepen K; Karlsson Hedestam GB; Wardemann H; Pulendran B; Doria-Rose NA; He WT; Juno JA; Ataca S; Wheatley AK; McLellan JS; Walker LM; Lederhofer J; Lindesmith LC; Wille H; Hotez PJ; Bekker LG
    Ann N Y Acad Sci; 2023 Jun; 1524(1):65-86. PubMed ID: 37020354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Existing antiviral vaccines.
    Ravanfar P; Satyaprakash A; Creed R; Mendoza N
    Dermatol Ther; 2009; 22(2):110-28. PubMed ID: 19335723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in the field of antiviral vaccines].
    Greco LM
    Ann Sclavo; 1980; 22(1):1-16. PubMed ID: 6264866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.
    Volz A; Sutter G
    Adv Virus Res; 2017; 97():187-243. PubMed ID: 28057259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Viruses to rescue health: Vaccination].
    Tangy F; Tournier JN
    Med Sci (Paris); 2022 Dec; 38(12):1052-1060. PubMed ID: 36692265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles, mumps, rubella, and varicella combination vaccine: safety and immunogenicity alone and in combination with other vaccines given to children. Measles, Mumps, Rubella, Varicella Vaccine Study Group.
    White CJ; Stinson D; Staehle B; Cho I; Matthews H; Ngai A; Keller P; Eiden J; Kuter B
    Clin Infect Dis; 1997 May; 24(5):925-31. PubMed ID: 9142794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in antiviral vaccine development.
    Graham BS
    Immunol Rev; 2013 Sep; 255(1):230-42. PubMed ID: 23947359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the development of inactivated virus vaccines.
    Stauffer F; El-Bacha T; Da Poian AT
    Recent Pat Antiinfect Drug Discov; 2006 Nov; 1(3):291-6. PubMed ID: 18221154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Live attenuated vaccines: Historical successes and current challenges.
    Minor PD
    Virology; 2015 May; 479-480():379-92. PubMed ID: 25864107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [What is the present status of the common virus vaccines?].
    Regnard J
    Nouv Presse Med; 1972 Jan; 1(1):33-8. PubMed ID: 5061188
    [No Abstract]   [Full Text] [Related]  

  • 15. Viral vaccines in historical perspective.
    Hilleman MR
    Dev Biol Stand; 1995; 84():107-16. PubMed ID: 7796942
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations.
    Wu JJ; Huang DB; Pang KR; Tyring SK
    J Am Acad Dermatol; 2004 Apr; 50(4):495-528; quiz 529-32. PubMed ID: 15034501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The WHO programme for prevention and control of viral, chlamydial, and rickettsial diseases. Brief review.
    Assaad FA; Schild GC
    Arch Virol; 1983; 76(4):275-88. PubMed ID: 6194771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles, mumps, rubella prevention: how can we do better?
    Kauffmann F; Heffernan C; Meurice F; Ota MOC; Vetter V; Casabona G
    Expert Rev Vaccines; 2021 Jul; 20(7):811-826. PubMed ID: 34096442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits, risks and costs of viral vaccines.
    Koplan JP; Axnick NW
    Prog Med Virol; 1982; 28():180-91. PubMed ID: 6806868
    [No Abstract]   [Full Text] [Related]  

  • 20. [The contribution of Pasteur Institute scientists to the development and study of the vaccine prevention of pediatric viral droplet infections].
    Boĭchuk LM; Shikina ES; Smorodintsev AA
    Tr Inst Im Pastera; 1985; 62():26-34. PubMed ID: 2954271
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.